文献速递糖尿病

1型糖尿病联邦医疗保险优势计划受益人中糖尿病技术使用的种族/民族不平等

Racial/Ethnic Inequities in Use of Diabetes Technologies Among Medicare Advantage Beneficiaries With Type 1 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

研究评估2017至2020年联邦医疗保险优势计划1型糖尿病受益人按种族/民族划分的持续葡萄糖监测(CGM)和胰岛素泵使用率变化,并分析社会经济因素的影响。结果显示所有种族/民族组技术使用均增加,但白人与黑人、西班牙裔及亚裔之间的差距在CGM使用上扩大,胰岛素泵使用差距变化不一,调整后不平等持续存在(P < .0001)。

要点

  • 2017至2020年所有种族/民族组糖尿病技术使用均增加。
  • 白人与黑人CGM使用绝对差异从2.6%扩大至11.1%,胰岛素泵差异稳定在10.7%至10.8%。
  • 调整人口学、社会经济状况和内分泌就诊后,种族/民族不平等仍持续(P < .0001)。

核心结论

  • 2017至2020年间,种族/民族组间糖尿病技术使用差异持续存在,且不能由人口学、社会经济状况或内分泌就诊解释。

研究设计与样本

  • 基于联邦医疗保险优势计划受益人的年度横断面分析,纳入2017至2020年每年有2次及以上糖尿病诊断索赔的1型糖尿病受益人。
  • 拟合模型预测技术使用,纳入年份、种族/民族、年龄、性别、内分泌就诊和社会经济状况指标。

主要发现

  • 所有种族/民族组技术使用从2017至2020年均增加。
  • 白人与黑人受益人胰岛素泵使用绝对差异从2017年10.7%至2020年10.8%保持稳定,CGM使用差异从2.6%扩大至11.1%。
  • 白人与西班牙裔受益人胰岛素泵使用差异从12.3%缩小至11.4%,CGM使用差异从3.0%扩大至15.5%。
  • 白人与亚裔受益人胰岛素泵使用差异从9.7%缩小至6.6%,CGM使用差异从1.5%扩大至8.0%。
  • 调整其他特征后,种族/民族不平等持续存在(P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Racial/ethnic inequities have been observed in diabetes care. OBJECTIVE: To measure changes in prevalence of continuous glucose monitoring (CGM) and insulin pump therapy among Medicare Advantage beneficiaries with type 1 diabetes by race/ethnicity and to determine the impact of socioeconomic factors on racial/ethnic inequities. DESIGN: The prevalence of CGM and pump use was assessed by race/ethnicity for Medicare Advantage beneficiaries annually from 2017 through 2020. Models predicting technology use by year, race/ethnicity, age, sex, endocrinology visits, and measures of socioeconomic status were fit. SETTING: Community. PATIENTS OR OTHER PARTICIPANTS: Beneficiaries with type 1 diabetes and 2 or more claims with a diabetes diagnosis in the coverage year. INTERVENTION(S): Insulin pump or CGM therapy. MAIN OUTCOME MEASURE(S): Use of diabetes technology by racial/ethnic group. RESULTS: Technology use increased from 2017 through 2020 in all racial/ethnic groups. The absolute difference in use between White and Black beneficiaries from 2017 to 2020 remained stable for insulin pumps (10.7% to 10.8%) and increased for CGM (2.6% to 11.1%). The differences in pump use from 2017 to 2020 narrowed between White and Hispanic beneficiaries (12.3% to 11.4%) and White and Asian beneficiaries (9.7% to 6.6%), whereas the opposite occurred for CGM use (3.0% to 15.5% for White vs Hispanic beneficiaries; 1.5% to 8.0% for White vs Asian beneficiaries). Racial/ethnic inequities persisted (P < .0001) after adjusting for other characteristics. CONCLUSIONS: Differences in diabetes technology use between racial/ethnic groups often persisted from 2017 through 2020 and could not be explained by demographics, socioeconomic status, or endocrinology visits.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kommareddi M, Wherry K, Vigersky RA, et al. Racial/Ethnic Inequities in Use of Diabetes Technologies Among Medicare Advantage Beneficiaries With Type 1 Diabetes. J Clin Endocrinol Metab. 2023. PMID: 36715293. doi:10.1210/clinem/dgad046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。